The UK and US have forged a key trade agreement that will keep zero duties on British pharmaceutical shipments going into the American market.
Agreement Details of the Accord
As part of the deal, the UK has committed to boost expenditure on pharmaceuticals through the public health system. This move secures that tariffs on these crucial exports will be held at nothing for a period of three years.
This development comes after previous threats to significantly raise tariffs on patented drug imports, with increases mentioned as high as 100%.
"This agreement with the Britain strengthens the international landscape for innovative medicines and brings much-needed balance to American-British drug exports," a release noted.
Trade Importance
Drugs represent one of the UK's biggest export categories to the America, which is easily the biggest buyer for major British pharmaceutical firms.
Trade data reveal that in the one-year period prior to the third quarter, the UK shipped pharmaceutical products totaling billions to the US. This figure made up 17.4% of total UK exports in that timeframe.
"This guarantee safeguards employment, increases investment and sets the stage for the UK to become a global hub for medical research," a minister commented.
Detailed NHS Changes
The agreement includes several notable pledges from the United Kingdom:
- Price Threshold Increase: The UK will raise the price threshold at which it judges new medicines to be prohibitively costly by a quarter.
- Boosted Medicine Funding: There is a target to double overall health service expenditure on drugs from 0.3 percent of the national economy to 0.6% over the following ten-year period.
- Refund Ceiling: The percentage pharmaceutical firms must pay back to the NHS to prevent overspending will be restricted at 15%. Last year, repayments exceeded twenty percent.
Recent Tensions
The deal takes place against a long-running dispute between the pharmaceutical industry and the British authorities over spending levels and approval rates.
These tensions were heightened by assertions that American consumers were charged significantly more for the equivalent treatments than consumers in the Britain and the EU.
Over the last 18 months, several major manufacturing plans in the UK have been delayed or scrapped, while major investments have been directed toward US facilities.
The Science Minister stated that the NHS had to increase expenditure on medicines, noting that its budget allocation on drugs had declined as a proportion of its overall budget over the past decade.
